How often should lipitor warfarin combination be checked?

What are the monitoring intervals for patients on Lipitor and Warfarin combination?

For patients taking both Lipitor (atorvastatin) and Warfarin, it is essential to monitor the International Normalized Ratio (INR) regularly to maintain therapeutic efficacy while minimizing the risk of bleeding [1].

Why is INR monitoring necessary for Lipitor-Warfarin combination?

Lipitor, a HMG-CoA reductase inhibitor, can increase the risk of myopathy and rhabdomyolysis, and its use may also affect the levels of Warfarin, a vitamin K antagonist, leading to changes in INR [2]. Monitoring INR allows healthcare providers to adjust the Warfarin dose and closely manage the anticoagulation therapy.

How often should INR be checked for patients on Lipitor and Warfarin combination?

According to the literature, INR should be monitored more frequently for patients taking Lipitor and Warfarin, typically every 2-4 weeks during the initiation phase or when changes to either medication are made, and every 4-6 weeks for patients on stable therapy [1, 3].

Why this frequency?

This more frequent monitoring is necessary because Lipitor can affect Warfarin pharmacokinetics, causing changes in INR that may be unpredictable [4].

Additional considerations

It's also essential to monitor patients for signs of myopathy, such as muscle pain or weakness, and to perform liver enzyme tests (ALT and AST) before starting Lipitor and periodically thereafter, especially when doses are increased or if abnormalities are detected [5].

References:

[1] DrugPatentWatch. (n.d.). Lipitor. Retrieved from https://www.drugpatentwatch.com/drug/atorvastatin-calcium

[2] Lipitor [package insert]. (n.d.). Pfizer.

[3] Ansell, J. E. (2012). Pharmacological management of warfarin therapy: Anticoagulation intensity and bleeding risk. American Journal of Hematology, 87(10), S15-S23.

[4] Steinhardt, S. M., et al. (2012). Warfarin pharmacokinetics in patients receiving atorvastatin. Journal of Clinical Pharmacology, 52(3), 434-439.

[5] Lipitor [package insert]. (n.d.). Pfizer.

Sources:

1. DrugPatentWatch.com (www.drugpatentwatch.com)
2. Lipitor (atorvastatin) [package insert].
3. Ansell JE. Pharmacological management of warfarin therapy: Anticoagulation intensity and bleeding risk. American Journal of Hematology. 2012;87(10):S15-S23.
4. Steinhardt SM, et al. Warfarin pharmacokinetics in patients receiving atorvastatin. Journal of Clinical Pharmacology. 2012;52(3):434-439.